Renovaro Inc., a leader in TechBio specializing in diagnostics, drug discovery, and cancer therapies, has announced an expedited trial date in its lawsuit against Predictive Oncology Inc. The litigation, filed on May 9, 2025, in the Delaware Court of Chancery, seeks to enforce a binding merger agreement initially executed on January 1, 2025. Renovaro alleges that Predictive Oncology breached provisions of the agreement by conducting a public offering of $545,000 in securities and attempting to terminate the agreement unilaterally without meaningful negotiations. Renovaro is pursuing specific performance, injunctive relief, and damages, with the case currently pending under Case No. 2025-0509.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.